Dravet syndrome

News

Case builds for Biogen, Stoke's Dravet syndrome drug

Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen.

News

Biogen bags rights to epilepsy drug from Stoke in $550m deal

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.

News

Epilepsy fail hands late-stage pipeline blow to Takeda

Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.

News

Zogenix gains Breakthrough status, but GW Pharma still ahead...

The FDA has granted Zogenix a Breakthrough Therapy Designation for its pipeline product, ZX008 for the treatment of seizures associated with Dravet syndrome.

Case builds for Biogen, Stoke's Dravet syndrome drug

Biogen bags rights to epilepsy drug from Stoke in $550m deal

Epilepsy fail hands late-stage pipeline blow to Takeda

Zogenix gains Breakthrough status, but GW Pharma still ahead...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Dravet syndrome

Editor's Picks